Robert Daly, MD, MBA, of Memorial Sloan Kettering Cancer Center, describes how new at-home treatment methods changed his delivery of care to patients with lung cancer.
Robert Daly, MD, MBA, of Memorial Sloan Kettering Cancer Center, discussed at-home lung cancer treatments and predicted how it and its benefits will continue to evolve.
Daly co-chaired The American Journal of Managed Care®’s Institute for Value-Based Medicine® held on November 2 in New York City, where presenters discussed at-home and remote cancer treatments. He is a thoracic oncologist who specializes in lung cancer, as well as a health services researcher interested in innovative cancer care systems.
Transcript
Could you explain how at-home or remote treatment methods have affected your delivery of care to patients?
A prime example of these new treatment methods is a pilot study we have ongoing right now at my institution where we're looking at the adoption of extended dosing of immunotherapy for patients with lung cancer. How we deliver that safely is by scheduling a televisit in between their infusional doses in order to do a toxicity check and ensure that they're tolerating the treatments safely.
These visits would otherwise have required those patients to come into the clinic in order to have that done. Now, we're able to do labs at the home and a televisit and provide that same service to ensure that they're getting their care safely.
So, what does that mean for patients? It means rather than having to come in every 3 weeks, they can now come in every 6 weeks. For patients who are working, for patients who have travel plans, for patients who have dependents that they're taking care of, this has had a huge impact on their quality of life.
In the future, what innovations or changes in lung cancer treatment do you anticipate to have the most significant impact on patient outcomes?
Well, one area where I'm really excited, and that ties together well with the virtual care, is subcutaneous immunotherapies. Now, there's the opportunity to potentially provide these lifesaving treatments for patients in the home because the delivery of those treatments now does not require an IV infusion.
So, that's a really exciting area where we could pair televisits, home labs, and subcutaneous injections to potentially untether patients from the cancer center and provide increased access to these treatments for patients not only nationally, but globally, as well.
Integrating RECIST and Clinician Approaches Boosts NSCLC Research
May 8th 2024Outcomes among patients with stage IV non–small cell lung cancer as evaluated within clinical trials via Response Evaluation Criteria in Solid Tumors (RECIST) and clinician response criteria in observational studies were compared for their concordance and reliability.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AA Unlikely to Cause Anxiety, Depression but May Be Affected by Mental Illness
May 7th 2024A Mendelian randomization study using genetic analysis found that alopecia areata (AA) increases the risk of anxiety and depression, but not the other way around, providing unique evidence for a causal link while adding to existing evidence.
Read More